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Abstract. Histone acetylation and deacetylation have been 
thought to be related to gene expression, and there are many 
reports indicating that histone deacetylase inhibitors (HDACis) 
exert antifibrogenic effects in several organs. In injured livers, 
hepatic stellate cells (HSCs) are activated in response to 
profibrogenic mediators and produce large amounts of extra-
cellular matrix. In particular, transforming growth factor-β1 
(TGF-β1) is considered as a key factor in accelerating hepatic 
fibrosis because it is released from activated HSCs and further 
stimulates them. The present study aimed to clarify whether 
sodium valproate (VPA) has suppressive effects on cultured 
human HSCs (LI90). We showed that treatment with VPA 
had no significantly suppressive effect on cell proliferation at 
a concentration of 1 mM, which corresponded approximately 
to the serum concentration obtained by the administration of 
a clinical dose. However, VPA prevented the morphological 
changes characteristic for activation and inhibited the expres-
sion of collagen type 1 α1 (COL1A1) and TGF-β1 in activated 
LI90 cells at the mRNA and protein levels. Our results support 
the hypothesis that VPA exerts antifibrogenic activity with 
little cytotoxicity at 1 mM, and HDACis are expected to be 
used in clinical practice for the treatment of fibrotic diseases.
Introduction
Hepatic stellate cells (HSCs) are considered as the main 
source of extracellular matrix (ECM) proteins in chronic 
liver diseases leading to fibrosis. In a normal liver, these 
cells are liver-specific pericytes that serve as major vitamin 
A storage sites and show little proliferative activity (1). In an 
injured liver, however, HSCs undergo phenotypic changes 
termed activation in response to profibrogenic mediators such 
as platelet-derived growth factor (PDGF), connective tissue 
growth factor (CTGF), endothelin (ET)-1, and members of 
the transforming growth factor-β (TGF-β) family. During this 
phenotypic transition, HSCs express α smooth muscle actin 
(αSMA) and acquire the capacity to proliferate and produce 
excessive quantities of ECM proteins (2,3). It is reported that 
TGF-β and its intracellular mediators, i.e., Smad proteins, play 
important roles in stimulating collagen synthesis. In particular, 
production of TGF-β1 is enhanced by activated HSCs, and 
it has been considered that the effects of TGF-β1 on HSCs 
involve predominantly autocrine stimulation (4,5). Therefore, 
inhibition of TGF-β1 signals seems to be a potential target for 
therapeutic intervention in patients with liver fibrosis.
It is considered that histone modification, particularly 
histone acetylation, is a key principle of epigenetic regulation 
of gene expression (6-8). Histone acetylation and deacety-
lation is controlled by histone acetyltransferases and histone 
deacetylases. In recent years, histone deacetylase inhibitors 
(HDACis) showed anti-cancer activities and are, therefore, of 
clinical interest (9-12). There are also several reports showing 
an antifibrogenic effect of HDACis, but the underlying mecha-
nism is still unclear (2,13-15).
In this study, we investigated the antifibrogenic effect of 
sodium valproate (VPA) on cultured HSCs and its molecular 
mechanism in vitro.
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Materials and methods
Chemicals. VPA (molecular weight: 166.2) and recombinant 
human TGF-β1 were purchased from Sigma-Aldrich (St. Louis, 
MO).
Antibodies. As primary antibodies, we used mouse monoclonal 
antibodies to αSMA and TGF-β1 (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA), rabbit polyclonal antibodies to collagen 
type 1 α1 (COL1A1), histone H3, H4, acetylated histone H3 
(Ac-H3), acetylated histone H4 (Ac-H4) (Millipore, Billerica, 
MA), Smad 7, phosphorylated Smad 2 (p-Smad 2), and phos-
phorylated Smad 3 (p-Smad 3), and a goat polyclonal antibody 
to Smad 2/3 (Santa Cruz Biotechnology).
Cell culture. Human hepatic stellate cells (LI90; Health 
Science Research Resources Bank, Osaka, Japan) were seeded 
at a density of 1.0x104 cells/ml in collagen type I-coated 
flasks, 96-well plates (Becton-Dickinson and Company, 
Franklin Lakes, NJ), or Lab-Tek chamber slides (Nalge Nunc 
International, New York, NY). The cells were cultured in 
Dulbecco's modified Eagle's medium (DMEM; Invitrogen, 
Tokyo, Japan) supplemented with 1% (v/v) heat-inactivated 
fetal bovine serum (FBS; Nichirei Biosciences, Inc., Tokyo, 
Japan), 100 U/ml penicillin, and 100 µg/ml streptomycin 
(Invitrogen) at 37˚C in a 5% CO2 humidified atmosphere 
for 24 h. On the following day, the medium was replaced 
with DMEM containing 1% FBS, antibiotics, and VPA and/
or TGF-β1 (3 ng/ml TGF-β1, 1 mM VPA, 3 ng/ml TGF-β1 
+ 1 mM VPA), and the cells were cultured for 7 more days. 
Normal control cells were cultured in DMEM containing 1% 
FBS and antibiotics. The medium was changed every day. At 
the end of culture, the following analyses were performed.
Cell viability analysis. Cell viability was assessed by using 
the CellTiter 96 AQueous One Solution Cell Proliferation 
assay (Promega Corp.oration, Fitchburg, WI) according 
to the manufacturer's instructions. Briefly, at the end of 
incubation, 20 µl of the reagent 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) was added to 100 µl medium in each well. Cells were 
further cultured for 1 h, and the resultant absorbance was 
recorded at 490 nm using a 96-well plate reader (EAR 340 AT, 
SLT, Vienna, Austria). Data represent the mean (SD) of three 
independent experiments and are expressed as percentage of 
untreated control cells.
Immunofluorescence. After culturing for 7 days on Lab-Tek 
chamber slides (Nalge Nunc International), cells were fixed 
in a mixture of methanol and acetone (1:1) for 15 min. 
Immunostaining was performed as described (16). Briefly, the 
slides were blocked with normal goat serum [5% in phosphate-
buffered saline (PBS)] and incubated with a mouse monoclonal 
antibody against αSMA (1:100) (Santa Cruz Biotechnology) 
or a rabbit polyclonal antibody to COL1A1 (1:100) (Santa 
Cruz Biotechnology) at 4˚C overnight. Next, the slides were 
washed in PBS and the immunoreactivity was visualized by 
incubating the slides with a goat anti-mouse IgG antibody 
conjugated with Alexa Fluor 488 (Invitrogen) (1:400) for 1 h 
at room temperature. The slides were counterstained with 
bis-benzimide (Hoechst 33258, 100 ng/ml; Sigma-Aldrich) to 
visualize the nuclei. The slides were then examined under a 
fluorescence microscope (Olympus BX51; Olympus, Tokyo, 
Japan).
Immunoblotting. The cells were harvested by trypsinization 
with 0.25% trypsin-EDTA (Invitrogen), washed 3 times with 
PBS, and dissolved in RIPA buffer (Wako Pure Chemical 
Industries, Ltd., Osaka, Japan) containing a protease and 
phosphatase inhibitor cocktail (Sigma-Aldrich). The protein 
concentration of each sample was measured using a BCA 
protein assay kit (Thermo Scientific, Waltham, MA). For 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), 20 µg protein of each sample were loaded on a 
5-20% gradient polyacrylamide gel (e-PAGEL, ATTO Corp., 
Tokyo, Japan). Proteins were transferred to polyvinylidene 
difluoride (PVDF) membranes (ATTO Corp.) and then blocked 
with gradient buffer (EzBlock, ATTO Corp.) at room tempera-
ture for 30 min. The membranes were incubated with a mouse 
anti-TGF-β1 antibody (1:1,000), a rabbit anti-COL1A1 antibody 
(1:1,000), anti-p-Smad 2 antibody (1:1,000), anti-p-Smad 3 anti-
body (1:1,000), anti-Smad 7 antibody (1:1,000), anti-histone H3 
antibody (1:5,000), anti-Ac-H3 antibody (1:5,000), anti-histone 
H4 antibody (1:5,000), anti-Ac-histone H4 antibody (1:5,000) 
and a goat anti-Smad 2/3 antibody (1:1,000) overnight at 4˚C. 
After washing with gradient buffer (EzWash, ATTO Corp.), 
the membranes were incubated with a horseradish peroxidase-
labeled anti-mouse or anti-rabbit IgG antibody (GE Healthcare 
UK, Ltd., Buckinghamshire, UK) or anti-goat IgG antibody 
(Santa Cruz Biotechnology) for 1 h at room temperature. The 
antibody-antigen complex was detected by using the ECL Plus 
Western blotting detection system (GE Healthcare) and quanti-
fied as described previously (17). We used β-actin as an internal 
control.
Quantitative real-time reverse transcription-polymerase 
chain reaction (real-time RT-PCR). Total-RNA was extracted 
from LI90 cells using the RNeasy mini kit (Qiagen, Venlo, 
Netherlands) according to the manufacturer's instructions. 
Next, 100 ng total-RNA were reverse transcribed to cDNA 
using the High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems, Foster City, CA). TaqMan quantitative 
real-time PCR was performed in triplicate on a Mx3005P 
Real-Time QPCR System (Agilent Technologies Japan, Ltd., 
Tokyo, Japan) using predesigned primer sets for COL1A1 
(assay ID Hs01076775_g1), TGF-β1 (assay ID Hs00998129_
m1) (TaqMan assays-on-demand, Applied Biosystems, 
Nieuwerkerk a/d IJssel, The Netherlands), and the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase 
[GAPDH; TaqMan GAPDH Control Reagents (Human)]. The 
cycling conditions consisted of polymerase activation at 95˚C 
for 10 min, followed by 40 cycles at 95˚C for 15 sec and 60˚C 
for 60 sec. Threshold cycle (Ct) values of the target genes 
were normalized to that of GAPDH. Relative expression in 
each sample compared to the control sample was calculated 
according to the 2-ΔΔCt method (18).
Statistical analysis. Statistical analyses were carried out using 
Welch's t-test. Probability values <0.05 were considered statis-
tically significant.
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Results
A high dose of VPA inhibits the proliferation of LI90 cells. 
First, we examined the effects of TGF-β1 or VPA on cell 
proliferation using the MTS assay as described above. 
Treatment with TGF-β1 did not show significant stimula-
tory or inhibitory effects on the proliferation of LI90 cells 
(Fig. 1A). Treatment with VPA reduced the cell number in a 
concentration-dependent manner (Fig. 1B). Statistically signif-
icant inhibition of cell proliferation after VPA exposure was 
observed at concentrations of 5 mM [69.8 (3.6)%, P=0.0047] 
and 10 mM [50.3 (4.2)%, P=0.0024], but the inhibition did not 
reach statistical significance at a concentration of 1 mM [91.2 
(8.5)%, P=0.21]. We also investigated the viability of the cells 
treated with TGF-β1 (3 ng/ml) and various concentrations of 
VPA (0.5, 1.0, 5.0 and 10 mM). Similar to treatment with VPA 
alone, significant inhibition was observed at concentrations 
≥5 mM (Fig. 1C).
VPA inhibits HSC activation at a concentration of 1 mM. 
To investigate whether VPA inhibits the activation of HSCs, 
we treated LI90 cells as indicated and performed immuno-
fluorescence studies. After incubation for 7 days, untreated 
LI90 cells showed myofibroblast-like morphology (Fig. 2A), 
and the morphological changes were accompanied by induc-
tion of αSMA expression (Fig. 3A). TGF-β1 accelerated these 
morphological alterations (Fig. 2C) and the expression of 
αSMA (Fig. 3C), while VPA inhibited the activation (Figs. 2B 
and 3B) and attenuated the TGF-β1-induced activation 
(Figs. 2D and 3D).
Figure 1. Treatment of LI90 cells with various concentrations of TGF-β1 or 
VPA. (A) A slight suppressive effect of TGF-β1 on cell proliferation. (B and C) 
Dose-dependent reduction of cell viability by VPA. VPA significantly inhibited 
cell proliferation at concentrations ≥5 mM. Data represent the mean (SD) of 
three independent experiments. Statistically significant differences were deter-
mined by the Welch's t-test. #P<0.01; NS, not significant; TGF-β1, transforming 
growth factor-β1; VPA, sodium valproate.
Figure 2. Phase contrast microscopic findings. (A and C) Untreated control 
group showed myofibroblast-like morphology after incubation for 7 days 
and TGF-β1 (3 ng/ml) accelerated the morphological change. VPA (1 mM) 
treatment inhibited the activation (B and D). TGF-β1, transforming growth 
factor-β1; VPA, sodium valproate.
Figure 3. Fluorescence immunocytochemistry for αSMA. (A) Activation of LI90 
cells is accompanied by induction of αSMA. (C) TGF-β1 (3 ng/ml) accelerated 
the activation. (B and D) HSCs treated with 1 mM VPA showed a decrease in 
αSMA fibers. αSMA, α smooth muscle actin; TGF-β1, transforming growth 
factor-β1; HSCs, hepatic stellate cells; VPA, sodium valproate.
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VPA attenuates TGF-β1-stimulated levels of COL1A1 protein 
and mRNA. Next, we evaluated the levels of COL1A1 expres-
sion in each group. TGF-β1-treated cells showed increased 
COL1A1 protein synthesis compared to control cells 
(Fig. 4A and C). Densitometry analysis of Western blot analyses 
of 3 separate experiments showed that the COL1A1 protein 
levels of the TGF-β1-treated group were significantly increased 
by 24.5% compared to that of the untreated group (P=0.042) 
(Fig. 5A and B). In our experiments, VPA scarcely influenced 
the basal COL1A1 protein expression (Figs. 4B and 5A and B), 
but it decreased the TGF-β1-stimulated COL1A1 protein 
expression by 17.8% (P=0.013) (Figs. 4D and 5A and B).
Similar to the changes at the protein level, TGF-β1 treat-
ment resulted in a statistically significant increase in COL1A1 
mRNA expression by 111% compared to that of the untreated 
cells (P=0.023) (Fig. 5C). The COL1A1 mRNA expression 
level of cells treated with VPA alone was almost the same 
as that of untreated cells, but VPA treatment suppressed the 
TGF-β1-induced up-regulation of COL1A1 mRNA (21.2%, 
P=0.0040) (Fig. 5C).
VPA treatment affects the expression of TGF-β1 at the protein 
and mRNA levels. We also examined whether VPA affects 
the expression of TGF-β1, which is an activator of HSCs. The 
expression of TGF-β1 following treatment with 3 ng/ml TGF-β1 
was increased by 76.3% compared to that of the controls 
(P=0.0023) (Fig. 6A and B). However, TGF-β1 expression of 
cells treated with 3 ng/ml TGF-β1 and 1 mM VPA was almost 
the same as that of the control cells. This finding indicated that 
VPA treatment attenuated the TGF-β1-induced up-regulation 
of TGF-β1 protein expression by 41.4% (P=0.0105). Following 
treatment with 3 ng/ml TGF-β1, the expression of TGF-β1 
mRNA was increased by 133% compared to that of the control 
cells (P=0.0008), and treatment with VPA and TGF-β1 resulted 
in a decrease in TGF-β1 mRNA expression of 59.6% (P=0.0015) 
(Fig. 6C). Similar to the expression of COL1A1, the protein and 
mRNA expression of TGF-β1 were not significantly altered by 
VPA treatment alone.
Expression and phosphorylation of Smad 2/3 are suppressed 
by VPA. Furthermore, we investigated the expression of Smad 
proteins, which are components of TGF-β signaling. The 
expression and phosphorylation of Smad 2/3 were up-regu-
lated in the presence of TGF-β1, and the TGF-β1-induced 
up-regulation was attenuated in the presence of VPA. In fact, 
changes in the expression of Smad 2/3 were similar to that 
observed for TGF-β1 (Fig. 7). VPA alone had no effect on the 
expression and phosphorylation of Smad 2/3. The expression 
of Smad 7 was not different in each group.
Figure 4. Immunofluorescence for COL1A1 in LI90 cells. (A) COL1A1 
protein synthesis in activated LI90 cells. (C) Acceleration of the synthesis 
of COL1A1 byTGF-β1. (B) VPA did not significantly influence the basal 
COL1A1 synthesis, but (D) it markedly attenuated the TGF-β1-induced up-
regulation of COL1A1 synthesis (D). COL1A1, collagen type 1 α 1; TGF-β1, 
transforming growth factor-β1; VPA, sodium valproate.
Figure 5. (A and B) Western blot analysis of COL1A1. VPA attenuated 
the TGF-β1-induced increase in COL1A1 protein expression by 17.8% 
(P=0.013). (C) Real-time RT-PCR for COL1A1 mRNA expression. TGF-β1 
markedly increased the COL1A1 mRNA expression compared to the control 
levels (P=0.023), and VPA suppressed the TGF-β1-stimulated up-regulation 
of COL1A1 mRNA expression (P=0.004). Data represent the mean (SD) of 
three independent experiments. Statistically significant differences were 
determined by the Welch's t-test. *P<0.05; #P<0.01; NS, not significant; 
COL1A1, collagen type 1 α 1; VPA, sodium valproate; RT-PCR, reverse 
transcriptase-polymerase chain reaction; TGF-β1, transforming growth 
factor-β1.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  28:  919-925,  2011 923
Hyperacetylation of histone H3 and H4 are maintained after 
7 days of treatment with VPA. In LI90 cells treated with VPA, 
we found increased levels of the acetylated histones H3 and 
H4 compared to cells not treated with VPA (Fig. 8).
Discussion
Histone modifications, such as acetylation, phosphorylation, 
methylation, and ubiquitination, have been shown to be a key 
regulatory mechanism of transcriptional regulation (6,19). 
Recent studies have shown that HDACis have the potential to 
inhibit carcinogenesis and fibrogenesis (2,9-15). VPA, a semi-
selective HDACi (20), is widely prescribed for patients with 
epilepsy and psychiatric disorders and well tolerated by the 
majority of patients (21,22). We examined whether VPA had 
antifibrogenic effects on human HSCs at a concentration of 
1 mM, which corresponded approximately to the serum levels 
obtained by administration of a clinical dose.
We first confirmed the effects of TGF-β1 and VPA on the 
proliferation of LI90 cells to determine the appropriate concen-
trations of these compounds used in the exposure experiments. 
In our experiments, TGF-β1 exerted no significant effect on the 
proliferation, with only a tendency for slight suppression. This 
result is in agreement with a previous report (23). In addition, 
Shirai et al (24) have shown that the plasma TGF-β1 levels in 
Figure 6. (A and B) Western blot analysis of TGF-β1. Treatment with TGF-β1 
increased the TGF-β1 protein expression by 73.6% compared to the untreated 
controls (P=0.0023). VPA attenuated the TGF-β1-induced up-regulation of 
the TGF-β1 protein expression by 41.4% (P=0.0105). (C) Real-time RT-PCR 
for TGF-β1 mRNA expression. TGF-β1 markedly increased the TGF-β1 
mRNA expression compared to the control level (P=0.0008), and VPA 
suppressed the TGF-β1-induced up-regulation of the TGF-β1 mRNA 
expression (P=0.0015). Data represent the mean (SD) of 3 different experi-
ments. Statistically significant differences were determined by the Welch's 
t-test. *P<0.05; #P<0.01; NS, not significant; TGF-β1, transforming growth 
factor-β1; RT-PCR, reverse transcriptase-polymerase chain reaction; VPA, 
sodium valproate.
Figure 7. Western blot analysis of Smad 2/3 and 7. The changes in the expres-
sion and phosphorylation of Smad 2/3 were similar to those observed for 
TGF-β1. Smad 7 was not influenced by TGF-β1 or VPA treatment. TGF-β1, 
transforming growth factor-β1; VPA, sodium valproate.
Figure 8. Western blot analysis of H3, H4, acetylated (Ac)-H3 and Ac-H4. 
VPA caused hyperacetylation of histone H3 and H4. VPA, sodium valproate.
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patients with chronic hepatitis was 3.0 (3.1) ng/ml [mean (SD)], 
and we thus considered it appropriate to expose LI90 cells to 
3 ng/ml TGF-β1 in order to mimic an injured liver. While 
VPA significantly inhibited the cell proliferation at concentra-
tions ≥5 mM or more, the decrease did not reach statistical 
significance at a concentration of 1 mM. This result indicated 
that VPA at a concentration of 1 mM had little cytotoxicity. 
In addition, according to a clinical trial of VPA in patients 
with refractory advanced cancer (25), the maximum serum 
concentration following intravenous administration of VPA 
(<60 mg/kg) did not exceed 200 mg/l and no dose-limiting 
toxicity was observed. On the basis of these facts, we decided 
to treat LI90 cells with 1 mM VPA. Treatment with 3 ng/ml 
TGF-β1 and 1 mM VPA also did not result in a significant 
decrease in the cell number compared to that of cells treated 
with TGF-β1 alone.
After treatment with 1 mM VPA alone for 7 days, a 
tendency for inhibition of morphological changes was 
observed, but we could not confirm a significant suppression 
of COL1A1 synthesis and TGF-β1 expression. It was reported 
that the synthesis of collagens and TGF-β1 were not effectively 
inhibited when transition into myofibroblasts had already 
occurred (1). We received LI90 cells from passages 16-18, and 
most of them showed myofibroblast-like morphology after 
24 h of incubation (data not shown). Therefore, we concluded 
that cells had been already activated when treatment with VPA 
began. This may also be the reason why VPA alone had no 
inhibitory effect on HSCs in our experiments.
Freshly isolated HSCs undergo transition from a quies-
cent to an activated phenotype after culture for a few days to 
about a week (1,26). The present study confirmed that exog-
enous TGF-β1 accelerated the phenotypic change and caused 
enhanced up-regulation of COL1A1 and TGF-β1 expression. 
As mentioned above, treatment with VPA alone had no signifi-
cant effects on the basal COL1A1 and TGF-β1 expression, 
but VPA at a concentration of 1 mM markedly attenuated 
the TGF-β1-induced up-regulation of COL1A1 synthesis. In 
addition, VPA reversed the TGF-β1-induced increase in the 
expression of TGF-β1 at the protein and mRNA levels to the 
control level. The present findings, therefore, suggest that the 
inhibitory effects of VPA on the collagen synthesis accelerated 
by exogenous TGF-β1 are, at least in part, due to suppression 
of TGF-β1 at the transcriptional level. Our data indicate that 
the changes in the Smad 2/3 expression are similar to those 
observed for TGF-β1. In addition, the expression of Smad 7 
was not altered in the presence of VPA. On the basis of these 
results, we conclude that VPA did not affect the expression of 
Smad proteins. It remains controversial whether HDACis act 
directly or indirectly on the expression and phosphorylation of 
Smad proteins (27,28).
After 7 days of incubation, acetylation of histone H3 and 
H4 of cells treated with VPA was maintained. Therefore, 
histone remodeling seemed to be associated with the antifibro-
genic effects shown in our study. Further studies are required 
to determine factors that affect the expression of TGF-β1 and 
to analyze the relationship between these factors and histone 
remodeling.
In conclusion, our study showed that the mechanism by 
which VPA acts on TGF-β1-induced hepatic fibrosis could be 
in part via the suppression of the transcription of TGF-β1 and 
that VPA is expected to be applied in clinical practice for the 
treatment of fibrotic diseases.
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